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1. Introduction 
Peripheral arterial disease affects approximately 12% of adults and 20% of adults over 70 
years (Hiatt et al., 1995). This disease results from one or more lesions in the arterial system 
of the lower extremity that restrict blood flow. The restriction of blood flow during 
ambulation may cause intermittent claudication, i.e. muscular pain due to lack of blood 
supply. About one fifth of people with peripheral arterial disease have intermittent 
claudication. About half of people with peripheral arterial disease are asymptomatic. A 
small part of people with peripheral arterial disease (< 10%) have critical limb ischemia, i.e. 
rest muscular pain and/or ischemic ulceration or gangrene of toes. Based on the severity of 
symptoms, the stages of the disease are classified as Fontaine stages I-IV, where stage I is 
asymptomatic, stage IIa is the occurrence of intermittent claudication after a pain-free 
walking distance of more than 200 m, stage IIb is intermittent claudication after less than 200 
m, stage III is rest pain, and stage IV is the presence of ischemic ulcers.  
Patients with peripheral arterial disease, which is an expression of systemic atherosclerosis, 
have an increased risk of cardiovascular events (Hankey et al., 2006). 
Medical therapy should include modification or elimination of atherosclerotic risk factors 
(cigarette smoking, diabetes mellitus, hypertension, hyperlipidemia), and antiplatelet 
therapies  to decrease  the risk of cardiovascular events and to improve survival. Moreover, 
the initial approach to the treatment of limb symptoms should focus to relieve discomfort, to 
improve exercise performance, and daily functional abilities by means of structured exercise 
and, in selected patients, pharmacotherapies to treat the exercise limitation of claudication 
(Norgren et al, 2007). Lower extremity revascularization is indicated for patients with a 
lifestyle-limiting disability due to intermittens claudication or with chronic critical limb 
ischemia (Hirsch et al., 2006; Norgren et al., 2007). 
There are two types of revascularization procedure: endovascular or surgical. Percutaneous 
transluminal angioplasty with or without stenting is an endovascular technique for 
revascularizing obstructed arteries. It was first introduced by Dotter and Judkins (Dotter & 
Judkins, 1964), and subsequently improved by Grüntzig (Grüntzig & Hopff, 1974). 
In peripheral transluminal angioplasty the recanalization of obstructed arteries is obtained by 
dilatation of a stenosis (i.e. a narrowing of the vessel diameter) or recanalization of a total 
occlusion, using a wire-guided inflatable balloon catheter. Usually the femoral artery in the 
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groin is cannulated and a deflated balloon catheter is inserted and pushed forward along the 
guide-wire to the sites of obstruction. Stenting is usually added to reduce the risk of 
reocclusion, especially if there is a major endothelial damage, arterial dissection or non-
satisfactory dilatation with relevant residual stenosis. Self-expanding metallic stents are 
mainly applied at the aortic bifurcation or iliac segments, whereas the femoropopliteal level, 
until recently, was associated with a higher risk for reocclusion due to smaller vessel diameters 
in distal arteries (Do et al., 1992; Mahler et al., 1999; Palmaz et al., 1985; Strecker et al., 1988). 
The implantation of drug-eluting stents, nitinol stents, paclitaxel-coated angioplasty 
balloons, or treatment by intravascular brachytherapy following peripheral angioplasty of 
the femoropopliteal arteries have been considered as interventions with the capacity of 
reducing the occurrence of restenosis/reocclusion  (Schillinger et al., 2006;  Gray et al., 2008). 
In patients with peripheral arterial disease endovascular procedures are generally the 
treatment of choice for short-segment iliac or femoral-popliteal artery lesions (TASC-A, 
single stenosis less than 3 cm long). Longer segment iliac or femoral-popliteal artery lesions 
(TASC-B, single iliac stenosis 5-10 cm long, two iliac lesions 3-5 cm long, single occlusion of 
an iliac artery, tandem femoral-popliteal stenoses less than 3 cm long, single femoral-
popliteal lesion 3-5 cm in length) are frequently treated by endovascular techniques 
(Norgren et al., 2007). 
Restenosis (or reocclusion) is the main complication of peripheral transluminal angioplasty. 
Balloon angioplasty has been shown to induce endothelial injury and oxidative stress with 
subsequent endothelial dysfunction, platelet aggregation, macrophage activation, and 
smooth muscle cell proliferation (McBride et al., 1988; Taniyama & Griendling, 2003). 
Peripheral transluminal angioplasty induces a prothrombotic condition: atherosclerotic 
plaques are disrupted and platelets aggregate at the site of the damaged arterial wall (Fuster 
et al., 1995). Thus, as a result of platelet aggregation, activated blood clotting in the damaged 
atheromatous artery and low shear stress, restenosis (or reocclusion) is frequent (Schwartz, 
1998; Wentzel et al., 2003). 
In particular, the effects of balloon angioplasty on the platelet activation have been studied 
previously in vitro and in vivo. Peripheral transluminal angioplasty has been shown to 
result in significant imbalance between the production of prostacyclin, an effective 
vasodilatator and platelet antiaggregator produced in endothelial cells, and thromboxane 
A2, a potent smooth muscle constrictor and platelet aggregator formed in platelets, with 
shift more toward increased thromboxane A2 production. This finding is suggestive of 
significant platelet activation and may have implication for future failure of peripheral 
angioplasty (Parmar et al., 2010). An increased formation of thromboxane A2 was also seen 
in other two studies, one in patients undergoing peripheral angioplasty and one in patients 
after coronary angioplasty (Rossi et al., 1997; Peterson et al., 1986). 
In addition, in the initial phase after balloon and stent procedures, coagulation system is 
activated, as demonstrated by increased serum levels of thrombin-antithrombin complexes, 
D-dimer and fibrinopeptide A. This condition favours early thrombotic occlusion, where 
’early’ is usually defined as a period covering the first 4 weeks after the intervention 
(Tsakiris et al., 1999; Tschöpl et al., 1997). Subsequently, intimal hyperplasia, a redundant 
healing of the arterial wall, which is responsible for restenosis and reocclusion in the mid- 
and long-term, may follow. Intimal hyperplasia occurs as a result of denudation (tearing off 
of the inner lining) of the endothelium caused by damage to the vessel wall with the 
catheter. Smooth muscle cells in the medial layer are stimulated to grow and migrate into 
the intimal layer (Haudenschild, 1995; Jørgensen et al., 1990). 
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Risk factors for restenosis/reocclusion include severity of atherosclerosis in run-off arteries, 
length of diseased segments, number of treated lesions, stage of disease, and presence of 
cardiovascular risk factors (Norgren et al., 2007). Female gender may be an independent 
predictor of decreased primary patency of external iliac artery stents (Timaran et al., 2001). 
Inflammation, revealed by an elevated C-reactive protein, was also considered as a risk 
factor for restenosis at six months after successful femoropopliteal angioplasty (Schillinger 
et al., 2002). 
The rate of restenosis/reocclusion of suprainguinal (iliac) arteries after peripheral 
transluminal angioplasty ranges from 14% after one year to 29% after 5 years, while the rate 
of restenosis/reocclusion of infrainguinal (femoropopliteal) arteries after peripheral 
transluminal angioplasty with or without stenting ranges from 23-35% after one year to  
45-58% after 5 years (Norgren et al., 2007). Patients with stenoses or occlusions of 
infrainguinal arteries of less than 3 cm had a favourable long-term patency rate of 74% 
(Gallino et al., 1984). 
Patients subjected to local thrombolysis show higher incidences of restenosis/reocclusion 
(Decrinis et al., 1993). 
It is important to define the lesion suitable for balloon angioplasty in both the suprainguinal 
and infrainguinal districts. 
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) 
redefined the indications for endovascular or surgical revascularization on the basis of 
anatomical characteristics of the lesions. Endovascular interventions are recommended  
for: i) unilateral or bilateral stenosis of common iliac artery; unilateral or bilateral single 
short (≤ 3 cm) stenosis of external iliac artery; ii) single stenosis ≤ 10 cm in length of 
femoropopliteal arteries; single occlusion ≤ 5 cm in length of femoropopliteal arteries (TASC 
Type A lesions) (Norgren et al., 2007). 
Endovascular interventions are the preferred treatments for: i) short (≤ 3 cm) stenosis of 
infrarenal aorta; unilateral common iliac artery occlusion; single or multiple stenosis totaling 
3-10 cm involving the external iliac artery not extending into the common femoral artery; 
unilateral external iliac artery occlusion not involving the origin of internal iliac or common 
femoral artery; ii) multiple lesions (stenoses or occlusions), each ≤ 5 cm of femoropopliteal 
segment; single stenosis or occlusion ≤ 15 cm not involving the infra geniculate popliteal 
artery; single or multiple lesions in the absence of continuous tibial vessels to improve 
inflow for a distal bypass; heavily calcified occlusion ≤ 5 cm in length; single popliteal 
stenosis (TASC Type B lesions) (Norgren et al., 2007). 
Provisional stent placement is indicated for iliac arteries as salvage therapy for a suboptimal 
or failed result from balloon dilatation (persistent translesional gradient, residual stenosis 
greater than 50%, flow-limiting dissection). Stenting is effective as primary therapy for 
common and external iliac artery stenoses and occlusions. Moreover, stents can be useful in 
the femoral, popliteal and tibial arteries as a salvage therapy for suboptimal or failed results 
from balloon dilatation (Hirsch et al., 2006). 
As mentioned above, the implantation of drug-eluting stents, nitinol stents, paclitaxel-
coated angioplasty balloons, or treatment by intravascular brachytherapy following 
peripheral angioplasty have been considered as interventions with the capacity of reducing 
the occurrence of restenosis/reocclusion. A study by Schillinger et al. showed better results 
at one year with self-expanding nitinol stent in femoropopliteal segments (Schillinger et al., 
2006). Use of paclitaxel-coated angioplasty balloons during percutaneous treatment of 
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femoropopliteal disease has been shown to be associated with significant reductions in late 
lumen loss (Tepe et al., 2008). Endovascular brachytherapy has been proposed as a 
promising treatment modality to reduce restenosis after angioplasty (Minar et al., 2000). 
However, the phenomenon of late acute thrombotic occlusion in patients receiving 
endovascular brachytherapy after stenting of the femoropopliteal arteries may compromise 
the benefits of endovascular radiation. The fact that late acute thrombotic occlusions occurs 
concomitantly with stopping clopidogrel in patients treated with a double antiplatelet 
regimen (aspirin 100 mg / day and clopidogrel 75 mg / day) suggests an intensive and 
prolonged antithrombotic prevention in these patients (Bonvini et al., 2003). 
There are much few data concerning antithrombotic therapy after peripheral arterial 
revascularization, and patients with peripheral arterial disease are often treated on the basis 
of experiences extrapolated from coronary arteries (Visonà et al., 2009). 
Antithrombotic therapy has been shown to lower the incidence of associated cardiovascular 
events (Sobel & Verhaeghe, 2008). A meta-analysis of 42 trials has shown a statistically 
significant 23% reduction of vascular events (vascular death, nonfatal myocardial infarction 
or stroke) in 9,214 patients with peripheral arterial disease treated with antiplatelet therapy. 
Even patients having peripheral angioplasty benefited to a similar degree (Antithrombotic 
Trialists' Collaboration, 2002). Clopidogrel seems to be superior to aspirin in reducing 
cardiovascular events, particularly in patients with peripheral arterial disease (relative risk 
reduction of 23%) (CAPRIE Steering Committee, 1996), but this advantage is minimal. Life-
long antiplatelet therapy is usually recommended for all patients with peripheral arterial 
disease to prevent death and disability from stroke and myocardial infarction.  
Antithrombotic drugs to prevent restenosis would make an important contribution to the 
sustained success of endovascular treatment. The main questions concern the most effective 
and safe antithrombotic therapy and its duration. 
2. Methods 
We performed a Medline search of English language studies published between 1976 and 
2010 with the keywords “antithrombotic therapy, peripheral angioplasty”. We also 
considered the reviews and meta-analyses. We selected two meta-analyses, two reviews, 
and fifteen original articles. 
3. Results 
Two meta-analyses and two reviews evaluated the efficacy and safety of antithrombotic 
agents for the prevention of restenosis after balloon angioplasty in patients with peripheral 
arterial disease (Girolami et al., 2000; Dörffler-Melly et al., 2005; Watson & Bergqvist, 2000; 
Visonà et al. 2009). 
The first meta-analysis evaluated the efficacy of conservative adjuvant therapy after 
endovascular or surgical revascularization procedures. The meta-analysis, including thirty-
two studies, showed that, compared to non-active control, aspirin (100-300 mg daily) with 
dipyridamole (225-450 mg daily) improves patency (odds ratio 0.69) and mortality (odds 
ratio 0.57). Similarly, ticlopidine has been shown to improve patency and amputation rates 
(odds ratio 0.53 and 1.01, respectively), and therefore may be used when aspirin is 
contraindicated. Data on the effectiveness of vitamin K inhibitors were not conclusive 
(Girolami et al., 2000). 
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The second meta-analysis is a Cochrane review of 14 randomized trials comparing different 
antithrombotic drugs (anticoagulants, antiplatelet agents and others) with no treatment or 
placebo to prevent restenosis/reocclusion following peripheral vascular treatment. The 
trials included patients with symptomatic peripheral arterial disease treated by 
endovascular revascularization of the iliac or femoropopliteal arteries. Various 
pharmacological interventions were analysed: anticoagulants, antiplatelet agents and other 
vasoactive drugs were compared with no treatment, placebo, or any other vasoactive drug. 
Clinical endpoints were reocclusion, amputation, death, myocardial infarction, stroke and 
major bleeding. The efficacy and safety of acetylsalcylic acid and low molecular weight 
heparins have been shown. Aspirin (50-300 mg daily) started prior to femoropopliteal 
peripheral transluminal angioplasty has been shown to be the most effective prophylactic 
treatment. Low molecular weight heparins seem to be more effective in preventing 
restenosis or reocclusion than unfractionated heparin (Dörffler-Melly et al., 2005). 
Watson and Bergqvist identified eleven randomized trials with antithrombotic agents, but 
they didn’t clarify their usefulness in reducing the likelihood of restenosis or reocclusion 
after balloon angioplasty of femoropopliteal lesions (Watson & Bergqvist, 2000). 
Our group recently conducted a review on antithrombotic therapy after peripheral 
angioplasty (Visonà et al., 2009). 
We analyse the studies identified in the following paragraphs (Table 1). 
3.1 Aspirin with or without dipyridamole 
Two studies compared aspirin combined with dipyridamole to placebo (Heiss et al., 1990; 
Study Group, 1994). 
In a single-center trial 199 patients undergoing balloon angioplasty of femoropopliteal 
arteries were randomized to high dose aspirin (990 mg) combined with dipyridamole (225 
mg), low dose aspirin (300 mg) plus dipyridamole (225 mg), or placebo. Clinical and 
angiographic improvement was observed in both treatment groups in comparison with 
placebo, but this was statistically significant only in the high-dose aspirin group (Heiss et al., 
1990). 
A multicenter study randomized 223 patients undergoing balloon angioplasty of iliac or 
femoropopliteal arteries to receive either placebo or aspirin (50 mg) plus dipyridamole (400 
mg). No difference was observed between the two groups. A possible explanation of this 
result may be a higher percentage of patients with more favourable iliac lesions in the 
placebo group (65% versus 51%). Moreover, use of metallic stents was not performed (Study 
Group, 1994). 
According the conclusions of the Cochrane review, a 60% reduction of restenosis/ 
reocclusion was found with aspirin 330 mg combined with dipyridamole as compared to 
placebo up to 12 months after angioplasty of femoropopliteal arteries. A similar positive 
effect on patency was found with aspirin 50 to 100 mg combined with dipyridamole as 
compared to placebo at 6 months, but this was not significant (Dörffler-Melly et al., 2005). 
Aspirin/dipyridamole showed a superior effect on patency after femoropopliteal 
angioplasty compared to vitamin K antagonists at 3, 6, and 12 months, but even this effect 
was not significant (Do & Mahler, 1994; Pilger et al. 1991). 
Aspirin 50 to 330 mg, with or without dipyridamole, started before femoropopliteal 
endovascular treatment, appeared to be the most effective and safest strategy, and reduced 
the incidence of restenosis/reocclusion at 6 and 12 months when compared with no therapy 
or vitamin K antagonists. Three trials compared the efficacy and safety of different doses of 
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aspirin after peripheral angioplasty. The doses tested ranged from 50 mg / day to 1000 mg / 
day. The three studies showed that higher doses of aspirin had no advantage on early 
reocclusion (within one month) and were more likely to cause gastrointestinal side effects 
including peptic ulcer (Weichert et al., 1994; Minar et al., 1995;  Ranke et al., 1994). 
3.2 Oral anticoagulants 
Anticoagulation is frequently combined with antiplatelet therapy after femoropopliteal or 
tibial artery balloon angioplasty, although the results of three randomized controlled trials 
do not support this practice (Schneider et al., 1987, as cited in Sobel & Verhaeghe, 2008; 
Pilger et al., 1991; Do & Mahler, 1994). In fact, in all three studies no significant difference 
was observed in arterial patency rate between the anticoagulation groups and the 
antiplatelet therapy groups (only slightly lower patency rate and more bleeding 
complications in the anticoagulation groups). 
3.3 Low molecular weight heparins 
Intimal hyperplasia is responsible for restenosis and reocclusion after angioplasty in the 
mid- and long-term. Low molecular weight heparins have been shown in experimental 
studies to have antiproliferative effects in addition to their antithrombotic properties 
(Wilson et al., 1991). Their potential to reduce restenosis remains to be established. The 
hypothesis that low molecular weight heparins plus aspirin are more effective than aspirin 
alone in reducing incidence of restenosis after peripheral transluminal angioplasty was 
tested in two trials. Nadroparin, administered at a dose adjusted to weight for 7 days after 
femoropopliteal angioplasty, has been shown to be more effective to prevent reocclusion at 
6 months than unfractionated heparin, without causing increased bleeding (Schweizer et al., 
2001). Despite this interesting result, dalteparin 2500 UI, administered for 3 months after 
femoropopliteal angioplasty plus aspirin 100 mg/day versus aspirin alone, failed to reduce 
incidence of restenosis/reocclusion at 12 months. However, dalteparin appeared to be 
beneficial at the 12-month follow-up in the subgroup of patients with critical limb ischemia 
(Koppensteiner et al., 2006). 
3.4 New antiplatelet drugs (abciximab, thienopyridines) 
There are few studies available on potent new antiplatelet drugs such as abciximab and 
thienopyridines. 
3.4.1 Abciximab 
In one study in high-risk patients with long segmental femoropopliteal interventions 
adjunctive administration of abciximab had a favorable effect on patency and clinical 
outcome in patients undergoing complex femoropopliteal catheter interventions not 
hampered by serious bleeding. Treatment effect of abciximab observed at 30 days was 
maintained at 6 months (Dörffler-Melly et al., 2005). 
In another study adjunctive abciximab after nitinol stenting of the superficial femoral artery 
did not appear to demonstrate any identifiable effect on functional outcomes at 9 months 
(Ansel et al., 2006). 
3.4.2 Thienopyridines 
The thienopyridines, ticlopidine and clopidogrel, interfere with the adenosine diphosphate 
(ADP) pathway. They might represent a useful alternative to aspirin, when it is not 
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tolerated, and might be combined with aspirin, when increased risk factors for 
restenosis/reocclusion are detected, although specific data are lacking. 
In one study ticlopidine was compared to vitamin K inhibitors. No significant difference in 
efficacy was found between the two drugs (Schneider et al., 1987, as cited in Sobel & 
Verhaeghe, 2008). 
The administration of clopidogrel and aspirin leads to a potent platelet inhibition, whose 
benefits have been demonstrated for patients with acute coronary syndrome, symptomatic 
vascular disease, and presence of multiple cardiovascular risk factors. A randomized double-
blind trial showed that the administration of clopidogrel and aspirin significantly suppresses 
platelet function up to 30 days after lower limb angioplasty, compared to aspirin and placebo 
(Cassar et al., 2005a). On the other hand, addition of clopidogrel to the standard 
antithrombotic therapy with aspirin had no effect on the levels of markers of coagulation 
activation, such as D-dimer and thrombin-antithrombin III, in patients with intermittent 
claudication before or after endovascular intervention (Cassar et al., 2005b). Moreover, therapy 
with clopidogrel and aspirin had no significant effect on markers of vascular smooth muscle 
cell proliferation before and after peripheral angioplasty (Wilson et al., 2009). 
3.4.3 Dual antiplatelet therapy 
Dual antiplatelet therapy (clopidogrel plus aspirin), leading to a potent platelet inhibition, 
has been shown to be more effective than aspirin alone in reducing cardiovascular events in 
patients with acute non-ST coronary syndrome. This finding has not been confirmed in 
patients at high cardiovascular risk but not in the acute phase, where risk-benefit ratio is less 
favourable (Keller et al., 2007). A potential benefit of clopidogrel and aspirin versus aspirin 
alone in patients with symptomatic vascular disease has been suggested by the CHARISMA 
trial, which enrolled more than 15,000 patients with either evident clinical cardiovascular 
disease or multiple risk factors (Bhatt et al., 2006). 
The benefit of more potent platelet inhibition with dual therapy, aspirin and clopidogrel, has 
been shown in a trial on acute coronary syndromes (CURE) (Fox et al., 2004). However, the 
efficacy and safety of this dual antiplatelet therapy after peripheral angioplasty have not 
been evaluated in a randomized controlled trial. The Clopidogrel and Aspirin in the 
Management of Peripheral Endovascular Revascularization study (CAMPER) was designed 
to evaluate this outcome after femoropopliteal angioplasty, but it was stopped, due to 
difficulties of randomization, perhaps because many patients were already treated off-label 
with clopidogrel and aspirin (Patrono et al., 2004).  
The administration of ticlopidine and acetylsalicylic acid has been shown to improve 
neurological outcome after carotid stenting without an additional increase in bleeding 
complications in patients undergoing carotid stenting, compared to acetylsalicylic acid alone 
(Dalainas et al., 2006). 
Aspirin and clopidogrel were used as standard therapy in two major randomized controlled 
trials of carotid stenting (preprocedure and at least for 30 days) (SPACE Collaborative 
Group, 2006; Mas et al., 2006). 
Although it is questionable to extrapolate experience from one anatomic region to another, in 
the absence of data on peripheral interventions, dual antiplatelet therapy seems to be a 
reasonable approach to reduce thrombotic complications after lower extremity balloon 
angioplasty and stenting, especially in the femoropopliteal and tibial districts. In fact, many 
physicians in the world use dual antiplatelet therapy with aspirin (100 mg / day) and 
clopidogrel (75 mg / day) before and after peripheral transluminal angioplasty and stenting of 
peripheral arteries. Dual antiplatelet therapy is continued for 4 weeks after the intervention. 
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Then aspirin is continued indefinitely (Visonà et al., 2009). Treatment with a loading dose of 
clopidogrel 6-24 hours before angioplasty seems to improve the clinical outcome (Verheugt et 
al., 2007), and a 600 mg loading dose versus 300 mg at least 12 hours before the procedure 
provides greater benefit in coronary syndromes (Cuisset et al., 2006). In addition, an intra-
arterial bolus of heparin (3000 to 5000 U) is often administered at the time of the procedure. 
 
Drugs Author, year Treatments Pts Design 
ASA ± 
dipyridamole 
 
Heiss, 1990 
 
 
 
Study Group, 
1994 
 
Hess, 1978 
 
 
Ranke, 1992 
 
 
Weichert, 
1994 
 
 
Minar, 1995 
ASA 300 mg / dipyridamole 225 mg 
ASA 990 mg /  dipyridamole 225 mg 
Placebo 
 
ASA 50 mg / dipyridamole 400 mg 
Placebo 
 
ASA 990 mg 
ASA 990 mg / dipirydamole 225 mg 
 
ASA 50 mg 
ASA 900 mg 
 
ASA 300 mg 
ASA 1000 mg 
 
ASA 100 mg 
ASA 1000 mg 
47 
51 
47 
 
105 
110 
 
50 
51 
 
184 
175 
 
106 
105 
 
105 
102 
 
R, DB, 1C 
 
 
 
R, DB, 
12C 
 
 
R, DB, 1C 
 
 
R, DB, 2C 
 
 
R, DB, 2C 
 
 
R, O, 1C 
Oral 
anticoagulants 
 
Do, 1994 
 
 
Pilger, 1991 
ASA 50 mg / dipyridamole 400 mg 
Anticoagulant 
 
ASA 500 mg / dipirydamole 225 mg 
Anticoagulant 
51 
61 
 
66 
63 
 
R, O, 1C 
 
 
R, O, 1C 
LMWHs 
 
Schweizer, 
2001 
 
Koppensteiner,  
2006 
Weight adjusted nadroparin + ASA 
100 mg 
Unfractionated heparin + ASA 100 mg 
 
Dalteparin 2500 IU + ASA 100 mg 
ASA 100 mg 
86 
86 
 
137 
138 
 
R, O, 1C 
 
 
R, O, 1C 
Ticlopidine 
 
Schneider, 
1987 
Ticlopidine 
Anticoagulant 
103 
94 
 
R, O, 3C 
Abciximab 
 
Dörffler-
Melly, 2005 
 
Ansel, 2006 
 
Abciximab + ASA 100 mg 
Placebo + ASA 100 mg 
 
Abciximab 
Placebo 
47 
51 
 
27 
24 
 
R, DB, 1C 
 
 
R, O, 1C 
Iloprost 
 
Horrocks, 
1997 
Iloprost 72 h + ASA 300 mg after 72 h 
ASA 300 mg 
None 72 h + ASA 300 mg after 72 h 
11 
13 
14 
 
R, O, 2C 
 
 
Cilostazol 
 
Iida, 2008 Cilostazol 200 mg 
Ticlopidine 200 mg 
63 
64 
 
R, O, 1C 
Pts= patients; ASA=acetylsalicylic acid; LMWHs=low molecular weight heparins; R=randomized; 
DB=double blind; O=open; nC=number of centres 
 
Table 1. Drugs, studies published, patients analysed and study designs 
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Currently, for patients undergoing lower extremity balloon angioplasty (with or without 
stenting), the American College of Chest Physicians (ACCP) recommends long-term aspirin 
(75-100 mg / day) (grade 1C), and recommends against anticoagulation with heparin or 
vitamin K inhibitors (grade 1A) (Sobel & Verhaeghe, 2008).     
Randomized, prospective studies with dual therapy are needed for resolving some issues, 
such as real efficacy of dual therapy in peripheral district, the optimal loading dose in 
patients undergoing endovascular revascularization, and the optimal duration of dual 
therapy following peripheral angioplasty and stenting (Plosker & Lyseng-Williamson, 2007). 
3.5 Vasoactive drugs 
Some drugs have interesting vasoactive properties, that may improve outcome after 
peripheral angioplasty. Iloprost, the prostacyclin analogue, and cilostazol, a 
phosphodiesterase type 3 inhibitor, have multiple effects, such as inhibition of platelet 
activation, vasodilation, antiproliferation of vascular smooth muscle cells, and improvement 
of endothelial cell function. These effects may lead to the inhibition of neointimal 
hyperplasia after stenting. 
Iloprost was investigated in a small study in conjunction with aspirin. A 3-day 
periinterventional intravenous infusion of iloprost plus long-term aspirin didn’t reduce 
incidence of restenosis, compared to aspirin alone (Horrocks et al., 1997). 
Cilostazol after endovascular therapy for femoropopliteal lesions was more effective in 
reducing restenosis than ticlopidine (Iida et al., 2008). 
Further studies are needed. 
4. Conclusion 
Patients with peripheral arterial disease benefit from receiving life-long aspirin at a daily 
dose of 75 mg to 100 mg or clopidogrel at a daily dose of 75 mg. Patients undergoing 
peripheral transluminal angioplasty should receive aspirin at a daily dose of 75 mg to 100 
mg, started before the intervention and continued life-long. Thienopyridines, e.g. 
clopidogrel, might represent a useful alternative to aspirin in cases of intolerance to aspirin. 
Although randomized clinical trials are lacking, it is reasonable to consider short-term dual 
antiplatelet therapy with aspirin and thienopyridines for infrainguinal stenting, given the 
relatively high rate of restenosis/reocclusion after interventions. It is reasonable to 
administer a 300-600 mg loading dose 6-24 hours before angioplasty, and to continue dual 
therapy for 4 weeks. If a drug-eluting peripheral stent was placed, dual therapy is 
maintained for 6-12 months. Use of low molecular weight heparins may be reserved for 
patients with critical limb iischemia. Abciximab may be useful after extended 
femoropopliteal interventions in patients at high risk of restenosis/reocclusion. 
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The field of performing transcatheter interventions to treat vascular lesions has exploded over the past 20
years. Not only has the technology changed, especially in the arena of balloon/stent devices, but the
techniques of approaching complex lesions has evolved over the past decade. Lesions that no one would have
imagined treating back in the 1990's are now being done routinely in the catheterization suite. This book
provides an update on the current techniques and devices used to treat a wide variety of lesions. Though, at
first, the outward appearance of the topics appears to be varied, they are all related by the common thread of
treating vascular lesions. We hope, by publishing this book, to accomplish two things: First, to offer insight from
experts in their field to treat, both medically and procedurally, complex vascular lesions that we frequently
encounter. Secondly, we hope to promote increased communication between areas of medicine that
frequently don't communicate, between adult interventional cardiologists, pediatric interventional cardiologists,
interventional radiologists, and neurosurgeons. Much can be learned from our respective colleagues in these
areas which can further our own world of interventions.
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